Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Endometrial Neoplasms 2Carcinosarcoma 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Salivary Gland Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Endometrioid 1Breast Neoplasms 1

Interventions

pembrolizumab 11Gemcitabine 10Doxorubicin 10Cyclophosphamide 9Specimen Handling 8Nivolumab 8Ibandronic Acid 8pazopanib 7Radiosurgery 6Magnetic Resonance Spectroscopy 6Imatinib Mesylate 6Biopsy 6Bevacizumab 6Irinotecan 5regorafenib 4Zoledronic Acid 4Ipilimumab 4Ifosfamide 4Fluorouracil 4Docetaxel 4Cetuximab 4sargramostim 3conatumumab 3cemiplimab 3Sunitinib 3Radiation 3Paclitaxel 3Leucovorin 3Cryosurgery 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × ceralasertib × Sarcoma × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡